Still, at least one biotech company whose shares are below $50 looks like a great buy: CRISPR Therapeutics (NASDAQ: CRSP). At least two factors have led to CRISPR Therapeutics' poor performance.

The S&P 500 and the Nasdaq 100 are having a good year with both indexes showing solid price gains from January to the present ...

“It is a true honor to be recognized as one of the top 50 companies in the IDC FinTech ... author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the ...